CORRESPONDENCE
Neil Skolnik, MD To the Editor: Clinicians need to be aware of the potential for cognitive bias in deciding how to use the results reported by Di Biase et al. 1 This study showed superiority of catheter ablation to amiodarone in maintaining normal sinus rhythm in the treatment of atrial fibrillation. Given this conclusion, the temptation for clinicians is to assume that catheter ablation is the preferred therapy for atrial fibrillation. This assumption represents commonly encountered, and potentially dangerous, cognitive biases. 2 These biases, specifically both framing bias and confirmation bias, occur when we are influenced by the way in which information is presented and interpret it in a manner that supports what we may already think. In this study, our interpretation of the information is framed by the comparison used and influenced by the belief that some treatment is better than no treatment at all.
When reading this study, it is easy to conclude that either ablation or antiarrhythmic therapy should be considered for atrial fibrillation, with efficacy favoring ablation. In fact, multiple studies of a rate control strategy alone versus antiarrhythmic therapy have shown no benefit of antiarrhythmic drugs in the outcomes of primary importance: stroke and mortality. In addition, a consistent nonsignificant signal of an increase in mortality is seen with antiarrhythmic treatment. 3, 4 This article occurs in the context of other articles published comparing catheter ablation with antiarrhythmic drugs as first-line treatment of atrial fibrillation. 5 It is important to be explicit about the fact that, when we view either antiarrhythmic drugs or ablation as the first-line options for atrial fibrillation, we will likely undervalue the option of not using rhythm control at all. An accurate conclusion to draw from this study, stripped of bias, would be that ablation yields a lower rate of recurrence in comparison with antiarrhythmic therapy, neither of which has been shown to be better than rate control.
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